Cellis

Executive Summary

Cellis is a Swiss-Polish biotech company pioneering cell-based oncology therapies with its proprietary Macrophage Drug Conjugate (MDC) platform. The MDC technology engineers therapeutic macrophages to deliver cytotoxic payloads directly into cancer cells, offering a novel approach to treat solid tumors with high unmet need. Founded in 2017 and headquartered in Geneva, Cellis leverages the unique tumor-homing and phagocytic properties of macrophages to overcome limitations of traditional antibody-drug conjugates and CAR-T therapies. While still in preclinical stages, the company aims to address key challenges in solid tumor treatment, including poor drug penetration and immunosuppressive tumor microenvironments. Cellis’s differentiated platform positions it as an emerging player in the cell and gene therapy landscape, with potential applications across multiple cancer types.

Upcoming Catalysts (preview)

• Q2 2026IND Filing for Lead MDC Candidate50% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference70% success
• Q3 2026Series A Financing Completion60% success